WO2009141532A3 - Derives de 1,5-diphenylepyrrole-3-carboxamide, leur preparation et leur utilisation comme antagonistes des recepteurs cb1 des cannabinoides - Google Patents

Derives de 1,5-diphenylepyrrole-3-carboxamide, leur preparation et leur utilisation comme antagonistes des recepteurs cb1 des cannabinoides Download PDF

Info

Publication number
WO2009141532A3
WO2009141532A3 PCT/FR2009/000535 FR2009000535W WO2009141532A3 WO 2009141532 A3 WO2009141532 A3 WO 2009141532A3 FR 2009000535 W FR2009000535 W FR 2009000535W WO 2009141532 A3 WO2009141532 A3 WO 2009141532A3
Authority
WO
WIPO (PCT)
Prior art keywords
cannabinoid
preparation
receptor antagonists
group
unsubstituted
Prior art date
Application number
PCT/FR2009/000535
Other languages
English (en)
Other versions
WO2009141532A2 (fr
Inventor
Francis Barth
Daniel Bichon
Christian Congy
Murielle Rinaldi-Carmona
Original Assignee
Sanofi-Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi-Aventis filed Critical Sanofi-Aventis
Priority to EP09750013A priority Critical patent/EP2283007A2/fr
Priority to JP2011507967A priority patent/JP5611193B2/ja
Publication of WO2009141532A2 publication Critical patent/WO2009141532A2/fr
Publication of WO2009141532A3 publication Critical patent/WO2009141532A3/fr
Priority to US12/942,780 priority patent/US8680102B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Abstract

L'invention a pour objet des composés répondant à la formule (I) dans laquelle : A représente un groupe alkylène en (C1-C6) non substitué ou substitué; R1 représente un atome d'hydrogène ou un groupe (C1-C4)alkyle non substitué ou substitué; R2 représente un radical homopipéridin-1-yle, pipéridin-1-yle, pyrrolidin-1-yle, azétidin-1-yle, un groupe amino (C1-C6)alkyle; ou R1 et R2 ensemble avec l'atome d'azote auquel ils sont liés constituent un radical pipérazin-1-yle, 1,4-diazépan-1-yle, homopipéridin-1-yle, pipéridin-1-yle, pyrrolidin-1-yle ou azétidin-1-yle; R3, R4, R5, R6, R7, R8 représentent chacun indépendamment un atome d'hydrogène, un atome d'halogène, un groupement -CN, -S(O)nR14; OS(O)nR14, un groupe (C1-C6)alkyle non substitué ou substitué; R9 représente un groupe -OR12, -CN, -CO2H, NR12R13, -CONR12R13, -NR15COR12, -CONHNH2, -CONHOH, -CONHSO2RH14, -S(O)nR14, -SO2NR12R13, -NR18SO2R14, -NR15SO2NR12R13, ou un hétérocycle aromatique. La présente invention concerne également les procédés de préparation et les applications thérapeutiques des composés de formule (I) en tant qu'antagonistes des récepteurs CB1 des cannabinoïdes.
PCT/FR2009/000535 2008-05-09 2009-05-07 Derives de pyrrole, leur preparation et leur application en therapeutique WO2009141532A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP09750013A EP2283007A2 (fr) 2008-05-09 2009-05-07 Dérivés de 1,5-diphénylepyrrole-3-carboxamide, leur preparation et leur utilisation comme antagonistes des récepteurs cb1 des cannabinoïdes
JP2011507967A JP5611193B2 (ja) 2008-05-09 2009-05-07 １，５−ジフェニルピロール−３−カルボキサミド誘導体、この調製、およびこのカンナビノイドｃｂ１受容体拮抗薬としての利用
US12/942,780 US8680102B2 (en) 2008-05-09 2010-11-09 Pyrrole derivatives, their preparation and their therapeutic application

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR08/02552 2008-05-09
FR0802552A FR2930939B1 (fr) 2008-05-09 2008-05-09 Derives de pyrrole, leur preparation et leur application en therapeutique

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12/942,780 Continuation US8680102B2 (en) 2008-05-09 2010-11-09 Pyrrole derivatives, their preparation and their therapeutic application

Publications (2)

Publication Number Publication Date
WO2009141532A2 WO2009141532A2 (fr) 2009-11-26
WO2009141532A3 true WO2009141532A3 (fr) 2010-02-11

Family

ID=39930534

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2009/000535 WO2009141532A2 (fr) 2008-05-09 2009-05-07 Derives de pyrrole, leur preparation et leur application en therapeutique

Country Status (10)

Country Link
US (1) US8680102B2 (fr)
EP (1) EP2283007A2 (fr)
JP (1) JP5611193B2 (fr)
AR (1) AR071688A1 (fr)
FR (1) FR2930939B1 (fr)
PA (1) PA8825701A1 (fr)
PE (1) PE20091830A1 (fr)
TW (1) TW200951120A (fr)
UY (1) UY31814A (fr)
WO (1) WO2009141532A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180022698A1 (en) 2014-10-16 2018-01-25 The Board Of Trustees Of The Leland Stanford Junior University Novel methods, compounds, and compositions for anesthesia
IL277071B1 (en) 2018-03-08 2024-03-01 Incyte Corp Aminopyrizine diol compounds as PI3K–y inhibitors
US11046658B2 (en) 2018-07-02 2021-06-29 Incyte Corporation Aminopyrazine derivatives as PI3K-γ inhibitors
WO2023089612A1 (fr) * 2021-11-19 2023-05-25 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Antagonistes périphériques du récepteur cb1 pour le traitement de symptômes du bas appareil urinaire (luts)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004058249A1 (fr) * 2002-12-24 2004-07-15 Astrazeneca Ab Derives de 1,5-diaryl-pyrrole-3-carboxamide et leur utilisation en tant que modulateurs des recepteurs des cannabinoides
WO2005080328A1 (fr) * 2004-02-20 2005-09-01 Astrazeneca Ab Derives de pyrrole-3-carboxamide utilises pour traiter l'obesite

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7271176B2 (en) 1998-09-04 2007-09-18 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use thereof
MXPA04002438A (es) 2001-09-24 2004-06-29 Bayer Pharmaceuticals Corp Preparacion y uso de derivados de pirroll para el tratamiento de la obesidad.
FR2874012B1 (fr) * 2004-08-09 2008-08-22 Sanofi Synthelabo Derives de pyrrole, leur preparation et leur utlisation en therapeutique
FR2882054B1 (fr) * 2005-02-17 2007-04-13 Sanofi Aventis Sa Derives de 1,5-diarylpyrrole, leur preparation et leur application en therapeutique
FR2887548B1 (fr) * 2005-06-27 2007-09-21 Sanofi Aventis Sa Derives de 4,5-diarylpyrrole, leur preparation et leur application en therapeutique
MX2008016338A (es) * 2006-06-27 2009-01-16 Abbott Lab Derivados de pirrol y sus metodos de uso.
FR2908766B1 (fr) * 2006-11-20 2009-01-09 Sanofi Aventis Sa Derives de pyrrole,leur preparation et leur utilisation en therapeutique.

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004058249A1 (fr) * 2002-12-24 2004-07-15 Astrazeneca Ab Derives de 1,5-diaryl-pyrrole-3-carboxamide et leur utilisation en tant que modulateurs des recepteurs des cannabinoides
WO2005080328A1 (fr) * 2004-02-20 2005-09-01 Astrazeneca Ab Derives de pyrrole-3-carboxamide utilises pour traiter l'obesite

Also Published As

Publication number Publication date
US8680102B2 (en) 2014-03-25
PA8825701A1 (es) 2009-12-16
JP5611193B2 (ja) 2014-10-22
TW200951120A (en) 2009-12-16
EP2283007A2 (fr) 2011-02-16
WO2009141532A2 (fr) 2009-11-26
JP2011519905A (ja) 2011-07-14
FR2930939A1 (fr) 2009-11-13
AR071688A1 (es) 2010-07-07
US20110152320A1 (en) 2011-06-23
PE20091830A1 (es) 2009-12-21
UY31814A (es) 2010-01-05
FR2930939B1 (fr) 2010-07-30

Similar Documents

Publication Publication Date Title
UA85079C2 (en) Derivatives of n-(1,5-diphenyl-1h-pyrazol-3-yl) sulphonamide with cb1 receptor affinity
MY143565A (en) Novel fluorocglycoside derivatives of pyrazoles: medicaments containing these compounds, and the use thereof
DK1713475T3 (da) 1,3,5-trisubstituerede 4,5-dihydro-1H-pyrazol-derivater med CB1-antagonistisk aktivitet
TW200510327A (en) 4-cyanopyrazole-3-carboxamide derivatives, their preparation, their therapeutic application
TW200612936A (en) Indole derivatives
MX2010003155A (es) Derivados de ciclopropil aril amida y uso de los mismos.
MXPA05007115A (es) Nuevos agonistas inversos del receptor cb 1.
MX2009002229A (es) Benzotriazoles como moduladores de cinasas.
ATE469892T1 (de) Substituierte 1h-dihydropyrazole, ihre herstellung und verwendung
HUP0303756A2 (hu) 1-Aril- vagy 1-alkilszulfonil-heterociklobenzazolok és eljárás ezek elõállítására és ezeket tartalmazó gyógyszerkészítmények
WO2006136859A3 (fr) Derives d'indolizine
WO2009010871A3 (fr) Nouveaux dérivés hétéroaryle servant d'antagonistes du récepteur a3 de l'adénosine
MXPA05007671A (es) Derivados de triazina como absorbedores de uv.
MX2007011698A (es) Derivados de oxindol sustituido, medicamentos que contienen dichos derivados y uso de los mismos.
TW200740781A (en) Novel compounds
HUP0400682A2 (hu) 5-Hidroxitriptamin-6-ligandumként használható heterociklilalkilindol- és -azaindol-származékok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
WO2009141532A3 (fr) Derives de 1,5-diphenylepyrrole-3-carboxamide, leur preparation et leur utilisation comme antagonistes des recepteurs cb1 des cannabinoides
DE502008001158D1 (en) Benzimidazolderivate
MY149649A (en) Indol-2-one derivatives disubstituted in the 3-position, preparation thereof and therapeutic use thereof
WO2008101247A3 (fr) Composes substitues en 6 presentant une affinite avec le recepteur 5-ht6
TW200610522A (en) Substituted ethane-1,2-diamines for the treatment of alzheimer's disease
TW200734336A (en) 6-Heteroarylpyridoindolone derivatives, preparation thereof and therapeutic use thereof
MXPA05010651A (es) Compuestos de pirazol.
TW200616948A (en) Pyrrole derivatives, preparation thereof and therapeutic use thereof
MXPA02011464A (es) Derivados 1,4-diazepan-2,5-diona y su uso como antagonistas del receptor de la nk-1.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09750013

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2011507967

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2009750013

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE